We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, and SMA.
Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance.
INVESTORS & MEDIA
INVESTOR OVERVIEW
There are currently no events to display.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>
Phase 2 Study of Reldesemtiv in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure Results from Phase 2 Clinical Trial of Reldesemtiv in Patients with COPD Expected in Q3 Finalizing Preparations to Initiate Second Phase 3
SOUTH SAN FRANCISCO, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
First Study of Muscle-Directed Therapy in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure SOUTH SAN FRANCISCO, Calif. , June 16, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced data from
SOUTH SAN FRANCISCO, Calif. , June 13, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018 at
